# US 2004/0081972 A1 · Novel physiologically active peptide and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081972 A1
- Document ID: US20040081972A1
- Status: Published application
- Kind: A1
- Application number: 10/343,462
- Filed: 2003-07-01
- Published: 2004-04-29
- Earliest claimed: 2000-08-01
- Inventors: Mitsuo Satoh; Kenji Shibata; Susumu Sekine; Masamichi Koike; Wataru Sakurai; Akiko Furuya; Katsuhiro Mori; Yoko Kato
- Web page: https://patentgrep.com/patent/US20040081972A1

## CPC

- C07K 14/52: Cytokines; Lymphokines; Interferons
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/02: for peripheral neuropathies
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/14: Decongestants or antiallergics
- A61P 27/16: Otologicals
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/47: from mammals
- A01K 2217/075: inducing loss of function, i.e. knock out
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a physiologically active peptide, a DNA encoding the peptide, an antibody which recognizes the peptide, and application methods thereof useful in screening and developing a therapeutic agent for diseases which accompany infection and inflammation, diseases which accompany abnormal differentiation and proliferation of smooth muscle cells, diseases which accompany abnormal activation of fibroblasts, diseases which accompany abnormal activation of a synovial tissue, diseases which accompany disorder of pancreatic β cells, diseases which accompany abnormality of osteoblasts or osteoclasts, diseases which accompany abnormal activation of immunocytes, diseases which accompany disorder of a blood vessel, diseases of an eye based on angiogenesis, diseases which accompany neopla, diseases in which linkage to gene regions of a major histocompatibility antigen is confirmed, and the like.

## Claims

### Claim 1

A peptide represented by the following formula (I):
R1-A-R2 (I)
(wherein R1 represents a hydrogen atom, substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, or substituted or unsubstituted heteroaryloxycarbonyl; R2 represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino; and A represents a peptide residue comprising an amino acid sequence selected from the group consisting of the following (a) to (1)), or a pharmaceutically acceptable salt thereof:
(a) the amino acid sequence represented by SEQ ID NO:1;
(b) the amino acid sequence represented by SEQ ID NO:2;
(c) the amino acid sequence represented by SEQ ID NO:3;
(d) the amino acid sequence represented by SEQ ID NO:4;
(e) the amino acid sequence represented by SEQ ID NO:5;
(f) the amino acid sequence represented by SEQ ID NO:6;
(g) an amino acid sequence comprising amino acids of positions 17 to 39 in the amino acid sequence represented by SEQ ID NO:1;
(h) an amino acid sequence comprising amino acids of positions 17 to 39 in the amino acid sequence represented by SEQ ID NO:2;
(i) an amino acid sequence comprising amino acids of positions 17 to 39 in the amino acid sequence represented by SEQ ID NO:3;
(i) an amino acid sequence comprising amino acids of positions 17 to 39 in the amino acid sequence represented by SEQ ID NO:4;
(k) an amino acid sequence comprising amino acids of positions 17 to 39 in th amino acid sequence r presented by SEQ ID NO:5;
(l) an amino acid sequence comprising amino acids of positions 17 to 39 in the amino acid sequence represented by SEQ ID NO:6.

### Claim 2

A peptide, which has an activity to change a concentration of an intercellular calcium ion, represented by the following formula (I):
R1-A-R2 (I)
(wherein R1 represents a hydrogen atom, substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, or substituted or unsubstituted heteroaryloxycarbonyl; R2 represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino; and A represents a peptide residue comprising an amino acid sequence in which one or more amino acid are substituted, deleted or added in the amino acid sequence selected from the group consisting of the following (a) to (1)), or a pharmaceutically acceptable salt thereof:
(a) the amino acid sequence represented by SEQ ID NO:1;
(b) the amino acid sequence represented by SEQ ID NO:2;
(c) the amino acid sequence represented by SEQ ID NO:3;
(d) the amino acid sequence represented by SEQ ID NO:4;
(e) the amino acid sequence represented by SEQ ID NO:5;
(f) the amino acid sequence represented by SEQ ID NO:6;
(g) an amino acid sequence comprising amino acids of positions 17 to 39 in the amino acid sequence represented by SEQ ID NO:1;
(h) an amino acid sequence comprising amino acids of positions 17 to. 39 in the amino acid sequence represented by SEQ ID NO:2;
(i) an amino acid sequence comprising amino acids of positions 17 to 39 in the amino acid sequence represented by SEQ ID NO:3;
(j) an amino acid sequence comprising amino acids of positions 17 to 39 in the amino acid sequence represented by SEQ ID NO:4;
(k) an amino acid sequence comprising amino acids of positions 17 to 39 in the amino acid sequence represented by SEQ ID NO:5;
(l) an amino acid sequence comprising amino acids of positions 17 to 39 in the amino acid sequence represented by SEQ ID NO:6.

### Claim 3

A peptide, which has an activity to change a concentration of an intracellular calcium ion, represented by the following formula (I):
R1-A-R2 (I)
(wherein R1 represents a hydrogen atom, substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, or substituted or unsubstituted heteroaryloxycarbonyl; R2 represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino; and A represents a peptide residue comprising an amino acid sequence having a homology of 60% or more with the amino acid sequence selected from the group consisting of the following (a) to (f)), or a pharmaceutically acceptable salt thereof:
(a) the amino acid sequence represented by SEQ ID NO:1;
(b) the amino acid sequence represented by SEQ ID NO:2;
(c) the amino acid sequence represented by SEQ ID NO:3;
(d) the amino acid sequence represented by SEQ ID NO:4;
(e) the amino acid sequence represented by SEQ ID NO:5;
(f) the amino acid sequence represented by SEQ ID NO:6.

### Claim 4 (depends on 2, 3)

The peptide according to claim 2 or 3, wherein the activity to change a concentration of an intracellular calcium ion is an activity to increase a concentration of an intracellular calcium ion, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 2, 3)

The peptide according to claim 2 or 3, wherein the cell is derived from a bone or a spleen, or a pharmaceutically acceptable salt thereof.

### Claim 6

A peptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences represented by SEQ ID NOs:36, 37, 38 and 10.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A DNA which encodes the peptide according to any one of claims 1 to 6.

### Claim 8

A DNA which comprises the nucleotide sequence represented by SEQ ID NO:11, 12, 13, 14, 15 or 16.

### Claim 9

A DNA which comprises a nucleotide sequence comprising nucleotides of positions 49 to 117 in the nucleotide sequence represented by SEQ ID NO:11, 12, 13, 14, 15 or 16.

### Claim 10 (depends on 7, 8, 9)

A DNA which hybridizes with the DNA according to any one of claims 7 to 9 under stringent conditions and has an activity to change a concentration of an intracellular calcium ion.

### Claim 11 (depends on 10)

The DNA according to claim 10, wherein the activity to change a concentration of an intracellular calcium ion is an activity to increase a concentration of an intracellular calcium ion.

### Claim 12 (depends on 10)

The DNA according to claim 10, wherein the cell is derived from a bone or a spleen.

### Claim 13 (depends on 7, 8, 9, 10, 11, 12)

A recombinant DNA which is obtainable by inserting the DNA according to any one of claims 7 to 12 into a vector.

### Claim 14 (depends on 13)

A transformant which is obtainable by introducing the recombinant DNA according to claim 13 into a host cell.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 14)

A process for producing a peptide, which comprises culturing the transformant according to claim 14 in a medium to thereby form and accumulate the peptide according to claim 1 to 6 in the culture, and recovering the peptide from the culture.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6)

An antibody which recognizes the peptide according to any one of claims 1 to 6.

### Claim 17 (depends on 16)

The antibody according to claim 16, which recognizes the amino acid sequence represented by SEQ ID NO:1 and recognizes the amino acid sequence represented by SEQ ID NO:5.

### Claim 18 (depends on 16, 17)

The antibody according to claim 16 or 17, which recognizes the peptide represented by SEQ ID NO:36 and recognizes the peptide represented by SEQ ID NO:38.

### Claim 19 (depends on 16)

The antibody according to claim 16, which recognizes the amino acid sequence represented by SEQ ID NO:1 but does not recognize the amino acid sequence represented by SEQ ID NO:5.

### Claim 20 (depends on 16, 19)

The antibody according to claim 16 or 19, which recognizes the peptide represented by SEQ ID NO:36 but does not recognize the peptide represented by SEQ ID NO:38.

### Claim 21 (depends on 16)

The antibody according to claim 16, which recognizes th amino acid sequence represented by SEQ ID NO:5 but does not recognize the amino acid sequence represented by SEQ ID NO:1.

### Claim 22 (depends on 16, 21)

The antibody according to claim 16 or 21, which recognizes the peptide represented by SEQ ID NO:38 but does not recognize the peptide represented by SEQ ID NO:36.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 16)

The antibody according to claim 16, which is an antibody having an activity to inhibit the peptide according to any one of claims 1 to 7.

### Claim 24 (depends on 23)

The antibody according to claim 23, wherein the peptide is represented by SEQ ID NO:36 or 38.

### Claim 25

A monoclonal antibody which is produced by a hybridoma KM2952 (FERM BP-7657).

### Claim 26

A monoclonal antibody which is produced by a hybridoma KM3022 (FERM BP-7658).

### Claim 27

A monoclonal antibody which is produced by a hybridoma KM3030 (FERM BP-7659).

### Claim 28

A monoclonal antibody which is produced by a hybridoma KM2947 (FERM BP-7656).

### Claim 29 (depends on 7, 8, 9, 10, 11, 12)

An oligonucleotide which corresponds to a sequence comprising continuous 5 to 60 nucleotides in the nucleotide sequence contained in the DNA according to any one of claims 7 to 12, or an oligonucleotide which corresponds to a sequence complementary to the oligonucleotide.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6)

A method for detecting expression of a gene encoding the peptide according to any one of claims 1 to 6 by hybridization, which comprises using the DNA according to any one of claims-7 to 12.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method for detecting mutation of a gene encoding the peptide according to any one of claims 1 to 6 by hybridization, which comprises using the DNA according to any one of claims 7 to 12.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

An immunological detection method of the peptide according to any one of claims 1 to 6, which comprises using the antibody according to any one of claims 16 to 28.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A tissue immunostaining method, which detecting the peptide according to any one of claims 1 to 6 by using the antibody according to any one of claims 16 to 28.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 29)

A method for detecting expression of a gene encoding the peptide according to any one of claims 1 to 6 by polymerase chain reaction, which comprises using the oligonucleotide according to claim 29.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 29)

A method for detecting variation of a gene encoding the peptide according to any one of claims 1 to 6 by polymerase chain reaction, which comprises using the oligonucleotide according to claim 29.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 29)

A method for inhibiting transcription of a gene or translation of a mRNA encoding the peptide according to any one of claims 1 to 6, which comprises using the DNA according to any one of claims 7 to 12 or the oligonucleotide according to claim 29.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 29)

A method for obtaining a promoter region of a gene encoding the peptide according to any one of claims 1 to 6, which comprise using the DNA according to any one of claims 7 to 12 or the oligonucleotide according to claim 29.

### Claim 38 (depends on 30, 31, 32, 33, 34, 35)

A method for diagnosing diseases which accompany infection and inflammation, diseases which accompany abnormal differentiation proliferation of a smooth muscle cell, diseases which accompany abnormal activation of a fibroblast, diseases which accompany abnormal activation of a synovial tissue, diseases which accompany disorder of a pancreatic β cell, diseases which accompany abnormality of an osteoblast or an osteoclast, diseases which accompany abnormal activation of an immunocyte, diseases which accompany disorder of blood vessel, diseases of an eye based on angiogenesis, diseases which accompany neopla or diseases in which linkage relation to a gene region of a major histocompatibility antigen is confirmed, which comprises using the method according to any one of claims 30 to 35.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6)

A medicament which comprises the peptide according to any one of claims 1 to 6 as an active ingredient.

### Claim 40 (depends on 7, 8, 9, 10, 11, 12)

A medicament which comprises the DNA according to any one of claims 7 to 12 as an active ingredient.

### Claim 41 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A medicament which comprises the antibody according to any one of claims 16 to 28 as an active ingredient.

### Claim 42 (depends on 29)

A medicament which comprises the oligonucleotide according to claim 29 as an active ingredient.

### Claim 43 (depends on 39, 40, 41, 42)

The medicament according to any one of claims 39 to 42, which is a medicament for diagnosing, treating or preventing diseases which accompany infection and inflammation, diseases which accompany abnormal differentiation proliferation of a smooth muscle cell, diseases which accompany abnormal activation of a fibroblast, diseases which accompany abnormal activation of a synovial tissue, diseases which accompany disorder of a pancreatic β cell, diseases which accompany abnormality of an osteoblast or an osteoclast, diseases which accompany abnormal activation of an immunocyte, diseases which accompany disorder of blood vessel, diseases of an eye based on angiogenesis, diseases which accompany neopla or diseases in which linkage relation to a gene region of a major histocompatibility antigen is confirmed.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6)

A method for screening a receptor which specifically interacts with the peptide according to any one of claims 1 to 6, which comprises using the peptide.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 44)

A receptor which specifically interacts with the peptide according to any one of claims 1 to 6 which is obtainable by the screening method according to claim 44.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6)

A knockout non-human animal in which expression of a gene encoding the peptide according to any one of claims 1 to 6 is partially or completely suspended.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6)

A knockout non-human animal in which the activity of the peptide according to any one of claims 1 to 6 is partially or completely suspended.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6)

A method for screening an agonist for the peptide according to any one of claims 1 to 6, which comprises using the peptide.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 48)

An agonist for the peptide according to any one of claims 1 to 6, which is identified by the method according to claim 48.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6)

A method for screening an antagonist for the peptide according to any one of claims 1 to 6, which comprises using the peptide.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 50)

An antagonist for the peptide according to any one of claims 1 to 6, which is identified by the method according to claim 50.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 14)

A method for analyzing expression of a gene encoding the peptide according to any one of claims 1 to 6, which comprises using the transformant according to claim 14.
